Xi’an DELI Biochemical Industry Co., Ltd. is pleased to announce its participation in CPHI Milan 2026, one of the major international events connecting pharmaceutical companies, pharmaceutical ingredient specialists, contract development and manufacturing organizations, distributors, and professionals across the global pharmaceutical supply chain.
CPHI Milan 2026 will take place from October 6 to 8, 2026, at Fiera Milano, Italy. Xi’an DELI will welcome pharmaceutical professionals and business partners at Booth 1H24, where our team will present a portfolio of pharmaceutical excipients, cyclodextrin derivatives, APIs, and pharmaceutical raw materials.
During the exhibition, visitors will have the opportunity to learn more about our three key cyclodextrin excipients, including Hydroxypropyl Betadex, Betadex Sulfobutyl Ether Sodium, and Beta-Cyclodextrin, as well as selected APIs including Glucosamine Sulfate Sodium Chloride, Menatetrenone, and L-Phenylalanine.
Founded in 1999, Xi’an DELI Biochemical Industry Co., Ltd. has more than 27 years of experience in the pharmaceutical ingredient industry. The company specializes in cyclodextrin derivatives and has developed a diversified portfolio of pharmaceutical excipients and active pharmaceutical ingredients.
Over the years, Xi’an DELI has focused on providing customers with stable product quality, consistent supply, responsive technical communication, and professional documentation support. Our products are used by customers involved in pharmaceutical formulation development, pharmaceutical manufacturing, research, distribution, and other applications.
At CPHI Milan 2026, our team looks forward to meeting both existing customers and new partners from Europe and other international markets. We welcome pharmaceutical companies, formulation development laboratories, CDMOs, distributors, purchasing teams, and other industry professionals to visit our booth and discuss potential cooperation.
Cyclodextrin derivatives are important pharmaceutical excipients that can be evaluated in formulation development, particularly for APIs where solubility, dissolution, or formulation performance presents a development challenge.
At CPHI Milan 2026, Xi’an DELI will highlight three cyclodextrin-based pharmaceutical excipients:
Hydroxypropyl Betadex (HPβCD) is a hydroxypropyl derivative of beta-cyclodextrin and is widely evaluated as a pharmaceutical excipient for formulation development.
Because of its high water solubility and ability to form inclusion complexes with suitable drug molecules, HPβCD can be considered in formulation strategies for poorly water-soluble APIs. It may be evaluated for solubility enhancement, drug-cyclodextrin complexation, and the development of oral or parenteral formulations.
Xi’an DELI provides pharmaceutical-grade HPβCD for customers involved in pharmaceutical research, formulation development, and commercial ingredient sourcing. Our team can support customers with product specifications, COA, samples, and relevant technical and regulatory documentation according to project requirements.
HPβCD will be one of the key products available for discussion at Booth 1H24, especially for customers working on:
Betadex Sulfobutyl Ether Sodium (SBECD) is another important cyclodextrin derivative in Xi’an DELI’s pharmaceutical excipient portfolio.
SBECD is an anionic cyclodextrin derivative that has been used in pharmaceutical formulations where improved solubilization of suitable APIs is required. It is particularly relevant to customers developing parenteral and injectable drug formulations.
Xi’an DELI offers pharmaceutical-grade SBECD for customers evaluating cyclodextrin-based solubility enhancement technologies. At CPHI Milan, our team can discuss product specifications, quality requirements, samples, technical documents, and potential commercial supply.
For customers evaluating both HPβCD and SBECD, DELI can also discuss the differences between these two cyclodextrin derivatives according to the characteristics of the target API and formulation requirements.
Beta-Cyclodextrin (β-CD) is the parent cyclodextrin structure used in the development of many cyclodextrin-based ingredients and derivatives. It can form inclusion complexes with suitable molecules and has applications across pharmaceutical, food, and biochemical fields.
With Beta-Cyclodextrin available alongside HPβCD and SBECD, Xi’an DELI can offer customers different cyclodextrin options according to their application and formulation development objectives.
In addition to cyclodextrin excipients, Xi’an DELI will showcase selected active pharmaceutical ingredients and pharmaceutical raw materials at CPHI Milan 2026. These products represent the company’s continued expansion of its pharmaceutical ingredient portfolio.
Glucosamine Sulfate Sodium Chloride is one of the APIs in Xi’an DELI’s pharmaceutical ingredient portfolio. Glucosamine-related pharmaceutical ingredients are widely associated with products developed for joint and musculoskeletal health.
At CPHI Milan 2026, visitors can discuss product specifications, quality documentation, packaging, samples, and potential supply arrangements with our team.
Menatetrenone is another API that Xi’an DELI will present at the exhibition. As part of our expanding API portfolio, Menatetrenone provides another pharmaceutical ingredient option for customers looking for reliable sources of pharmaceutical raw materials.
Our team will be available at Booth 1H24 to discuss product specifications, documentation, development requirements, sample evaluation, and potential long-term cooperation.
L-Phenylalanine is an amino acid ingredient with applications in pharmaceutical, nutritional, and biochemical fields. Xi’an DELI is expanding its product portfolio to provide customers with a broader range of pharmaceutical and biochemical raw materials.
Customers interested in L-Phenylalanine can meet with our team at CPHI Milan to discuss product specifications, quality requirements, packaging, samples, and international supply opportunities.
For pharmaceutical ingredient customers, product quality is only one part of supplier selection. Consistent supply, documentation, technical communication, sample support, and long-term cooperation are also important factors.
Xi’an DELI aims to support customers through different stages of product evaluation and procurement. For new projects, customers can begin with sample evaluation and review product specifications and COA. Depending on project requirements, additional technical and regulatory documents can be provided for internal evaluation and supplier qualification.
For formulation development projects involving HPβCD or SBECD, customers can discuss their API characteristics and formulation objectives with our team. Topics may include solubility enhancement, dosage form, target concentration, quality specifications, product grade, and documentation requirements.
After successful technical and quality evaluation, Xi’an DELI can continue to support customers as projects move from development quantities toward regular commercial supply.
Our objective is to build long-term cooperation based on stable supply, consistent product quality, professional communication, technical support, and reliable service.
Xi’an DELI understands that pharmaceutical customers require comprehensive information when evaluating a new ingredient supplier. Therefore, we provide relevant quality and technical documentation according to the product and customer requirements.
Available documentation may include COA, product specifications, technical documents, regulatory information, and other supporting documents where applicable.
For cyclodextrin derivatives, customers can discuss their specific formulation or application requirements with our team before selecting a suitable product for evaluation.
For HPβCD and SBECD projects, our team can also provide technical information to help customers understand the characteristics and potential applications of different cyclodextrin derivatives.
CPHI Milan provides an important opportunity for pharmaceutical professionals to meet face-to-face and explore new partnerships across the global pharmaceutical supply chain.
For Xi’an DELI, CPHI Milan 2026 is an opportunity to meet existing customers, reconnect with previous contacts, and establish new relationships with pharmaceutical companies, CDMOs, distributors, formulation developers, purchasing teams, and other industry professionals.
Visitors to our booth can discuss:
We sincerely invite pharmaceutical professionals, formulation developers, procurement teams, distributors, CDMOs, and potential business partners to visit Xi’an DELI Biochemical Industry Co., Ltd. at Booth 1H24 during CPHI Milan 2026.
Whether you are looking for HPβCD, SBECD, Beta-Cyclodextrin, Glucosamine Sulfate Sodium Chloride, Menatetrenone, L-Phenylalanine, or other pharmaceutical ingredients, our team will be pleased to discuss your requirements.
If you are evaluating a new pharmaceutical excipient, searching for an alternative source, preparing a formulation development project, or looking for a long-term pharmaceutical ingredient partner, we welcome the opportunity to meet with you in Milan.
Event: CPHI Milan 2026
Date: October 6–8, 2026
Venue: Fiera Milano, Italy
Booth: 1H24
Company: Xi’an DELI Biochemical Industry Co., Ltd.
We look forward to meeting you in Milan and exploring new opportunities for cooperation.
See you at CPHI Milan 2026!
